Affiliation:
1. Luther College , Decorah, Iowa, USA
2. Mayo Clinic , Rochester, Minnesota, USA
3. University of Illinois Urbana-Champaign , Champaign, Illinois, USA
4. University of Texas Health Science Center , Houston, Texas, USA
Abstract
Abstract
Background
Alzheimer’s disease (AD) is a progressive neurological disorder with no specific curative medications. Sophisticated clinical skills are crucial to optimize treatment regimens given the multiple coexisting comorbidities in the patient population.
Objective
Here, we propose a study to leverage reinforcement learning (RL) to learn the clinicians’ decisions for AD patients based on the longitude data from electronic health records.
Methods
In this study, we selected 1736 patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. We focused on the two most frequent concomitant diseases—depression, and hypertension, thus creating 5 data cohorts (ie, Whole Data, AD, AD-Hypertension, AD-Depression, and AD-Depression-Hypertension). We modeled the treatment learning into an RL problem by defining states, actions, and rewards. We built a regression model and decision tree to generate multiple states, used six combinations of medications (ie, cholinesterase inhibitors, memantine, memantine-cholinesterase inhibitors, hypertension drugs, supplements, or no drugs) as actions, and Mini-Mental State Exam (MMSE) scores as rewards.
Results
Given the proper dataset, the RL model can generate an optimal policy (regimen plan) that outperforms the clinician’s treatment regimen. Optimal policies (ie, policy iteration and Q-learning) had lower rewards than the clinician’s policy (mean −3.03 and −2.93 vs. −2.93, respectively) for smaller datasets but had higher rewards for larger datasets (mean −4.68 and −2.82 vs. −4.57, respectively).
Conclusions
Our results highlight the potential of using RL to generate the optimal treatment based on the patients’ longitude records. Our work can lead the path towards developing RL-based decision support systems that could help manage AD with comorbidities.
Funder
National Institute of Health
NIGMS
Alzheimer’s Disease Neuroimaging Initiative
National Institutes of Health
Department of Defense
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Bristol-Myers Squibb Company
CereSpir, Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun; F. Hoffmann-La Roche Ltd
Janssen Alzheimer Immunotherapy Research & Development, LLC
The Canadian Institutes of Health Research
Publisher
Oxford University Press (OUP)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献